New and highly sensitive ELISA technique for bioanalysis of bevacizumab

(Bentham Science Publishers) Bevacizumab is an anti-growth factor vascular endothelial growth factor (VEGF) monoclonal antibody, it is the antiangiogenic agent at the most advanced stage of development in the treatment of NSCLC.This drug was selected because of its inter individual differences in clinical response, its therapeutic importance in the treatment of non-small cell lung cancer (NSCLC).
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news